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ABSTRACT
Aberrant wound healing presents as inappropriate or insufficient tissue formation. Using a
model of musculoskeletal injury, we demonstrate that loss of transforming growth factor-β acti-
vated kinase 1 (TAK1) signaling reduces inappropriate tissue formation (heterotopic ossification)
through reduced cellular differentiation. Upon identifying increased proliferation with loss of
TAK1 signaling, we considered a regenerative approach to address insufficient tissue production
through coordinated inactivation of TAK1 to promote cellular proliferation, followed by reactiva-
tion to elicit differentiation and extracellular matrix production. Although the current regenera-
tive medicine paradigm is centered on the effects of drug treatment (“drug on”), the impact of
drug withdrawal (“drug off”) implicit in these regimens is unknown. Because current TAK1 inhibi-
tors are unable to phenocopy genetic Tak1 loss, we introduce the dual-inducible COmbinational
Sequential Inversion ENgineering (COSIEN) mouse model. The COSIEN mouse model, which
allows us to study the response to targeted drug treatment (“drug on”) and subsequent with-
drawal (“drug off”) through genetic modification, was used here to inactivate and reactivate
Tak1 with the purpose of augmenting tissue regeneration in a calvarial defect model. Our study
reveals the importance of both the “drug on” (Cre-mediated inactivation) and “drug off”
(Flp-mediated reactivation) states during regenerative therapy using a mouse model with broad
utility to study targeted therapies for disease. STEM CELLS 2019;37:766–778
SIGNIFICANCE STATEMENT
This study targets the transforming growth factor-β activated kinase 1 (TAK1) pathway to reduce
heterotopic ossification, a pathologic condition in which bone develops within muscle or soft tis-
sues. It shows that Tak1 knockout leads to cellular proliferation; this can be harnessed to increase
the number of cells present at the injury site. Using a mouse model, the Tak1 gene was inacti-
vated and reactivated. It showed that inactivation and reactivation of Tak1 can improve bony
healing through the coordination of increased proliferation (inactivation) followed by differentia-
tion (reactivation). This approach elucidates a new paradigm in regenerative medicine in which
coordination between treatment and withdrawal of treatment can augment healing.
INTRODUCTION
Normal tissue regeneration requires coordina-
tion between cellular proliferation and subse-
quent differentiation. Any disturbance of this
coordinated balance leads to pathologic wound
healing after injury, as observed in patients
with heterotopic ossification (HO). Current state
of knowledge on tissue engineering-based
approaches for wound regeneration is based on
cell transplantation and biomaterials [1–3]. Addi-
tionally, approaches with small-molecules modify
pathways responsible for cellular proliferation/
apoptosis [4–7] or differentiation [8–13], but
typically not both.
HO is a condition in which extraskeletal
bone forms in response to local tissue injury;
although HO has primarily been studied in the
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context of genetic mutations in type I bone morphogenetic
protein receptors [14–17], it also is known to form in patients
after severe trauma without genetic mutations (e.g., trauma-
induced HO [tHO]) [14, 18–20]. Recently, we have shown that
tHO is caused by pathologic cellular proliferation and subse-
quent differentiation through a cartilaginous intermediary [14, 20],
prompting us to study transforming growth factor-β (TGF-β), a
known mediator of cartilage formation [21–27], in HO. Here,
we specifically focus on the TGF-β activated kinase 1 (TAK1)
signaling pathway [23, 24, 26, 28] to coordinate cellular prolif-
eration and differentiation to reduce HO or improve bony cal-
varial healing.
TGF-β activating kinase 1 (TAK1) is a key regulator of mitogen-
activated protein kinases (MAPK) kinase activation in TGF-β
and bone morphogenetic protein (BMP) signaling pathways
[27]. In adults, TAK1 has diverse roles spanning inflammation
and the immune response, wound healing, fibrosis, and onco-
genesis [23, 24, 26, 28–31]. During development, TAK1 is critical
for the proliferation and maturation of bone, cartilage, skin,
and vascular endothelium and is a major regulator of the con-
densation, proliferation, and differentiation of early mesenchy-
mal population. Mechanistically, TAK1 transduces signals to
several downstream signaling cascades, including mitogen-
activated protein kinase 4/7 (MKK4/7)-c-Jun N-terminal kinases,
MKK3/6-p38 MAPK, and nuclear factor-kappa β (NF-κB)-inducing
kinase-IκB kinase. TAK1 is necessary for propagation of both
SMAD-dependent and independent (p38 MAPK) BMP signaling
pathways [23, 24, 26, 28]. Furthermore, TAK1 is central to
cytokine-induced activation of NF-κB via interleukin 1-β [32].
To coordinate the TAK1 signaling pathway, we generated a
novel genetic mouse model (Cre/Flp mouse) which allows Tak1
to be knocked out using Cre/lox technology (fx) and subse-
quently reactivated using Flp/Frt technology (frt) [32]. The
resulted COmbinational Sequential Inversion ENgineering (COSIEN)
mouse allows us to elucidate a “drug on”/“drug off” therapeu-
tic paradigm to optimize bone regeneration. Our findings sug-
gest that precise regulation of TAK1 allows for control of the
proliferation-differentiation switch in stem cell/progenitor pop-
ulation at the wound site (Supporting Information Fig. S1). Our
system demonstrates the potential for therapeutic leverage of
a central regulatory protein to affect wound healing in both
physiologic and pathologic models.
MATERIALS AND METHODS
Ethics Statement
All animal experiments described were approved by the Uni-
versity Committee on Use and Care of Animals at the Univer-
sity of Michigan-Ann Arbor (Protocols: #05909, 05182, 05716,
and 07715). This study was carried out in strict accordance
with the recommendations in the Guide for the Use and Care
of Laboratory Animals from the Institute for Laboratory Animal
Research (2011). All animals were housed in Institutional Animal
Care and Use Committees (IACUC)-supervised facilities, not to
exceed five mice housed per cage at 18C–22C, 12-hour light–
dark cycle with ad libitum access to food and water.
Animals
All mice used in this study were derived from a C57BL/6 back-
ground. Adult 6- to 8-week-old wild-type C57BL/6 (Charles River
Laboratory, Boston, MA) mice were included as controls. Mutant
mice used in this study included tamoxifen-inducible postnatal
Tak1 knockout (Tak1 tmKO: Ub.CreERT/Tak1fl-frt/fl-frt), condi-
tional Tak1 knockout (Tak1 cKO: Prx.Cre/Tak1fl-frt/fl-frt), dual
inducible Tak1 knockout (Tak1fl-frt/fl-frt), and their respective lit-
termate controls. All breeding was performed at the University
of Michigan in facilities managed by the Unit for Laboratory Ani-
mal Medicine. Tail genomic DNA was used for genotyping.
Generation of Dual Inducible COSIEN Mouse for
Inactivation and Reactivation of Tak1
Exon 2 of Tak1 was targeted because removal of exon 2 has
been shown to be sufficient to disrupt gene function [30]. A
4.5-kb fragment containing intron 1 of Tak1 locus was poly-
merse chain reaction (PCR) amplified from 129SvEv genomic
DNA with Phusion polymerase (New England Biolabs, Inc.,
MA). A 2.8-kb fragment containing exon 2 and 3.6-kb fragment
containing intron 2 were PCR amplified. After amplification,
these fragments were ligated with mutant loxP sites, mutant
FRT sites, a PGK-Neo cassette, and DTA cassette to generate a
targeting vector (Supporting Information Figs. S1, S2). The posi-
tions of the probes used for Southern analysis and positions of
PCR genotyping primers are shown. The sizes of the restriction
fragments detected by these probes in WT and targeted DNA
are shown above or below the locus. A 50 and 30 loxP–FRT sites
are marked with an EcoRV and a HindIII sites, respectively.
Since both loxP sites and FRT sites are placed in the locus in
an opposite direction, recombinase-mediated DNA recombina-
tion flips the sequence between instead of its deletion. To avoid
continuous flipping and allow for one-time recombination, we
introduced mutations in each recognition site. Lox66 has muta-
tions in five bases at the most 30 region whereas Lox72 has
mutations in the most 50 region [38]. FRT GS1-1 has a single
base change in 50 arm whereas FRT GS2-1 has a single base
change in 30 arm [39]. Cre-mediated DNA recombination flips
the sequence between Lox66 and Lox72, but after recombina-
tion, one of the resulted LoxP sequences bears mutations in
both 50 and 30 arms, which no longer can be a substrate for Cre
recombinase. Thus, exon 2 will be flipped by Cre recombinase
only one time and gene function will be lost (Supporting Infor-
mation Fig. S2). Flippase-mediated DNA recombination flips the
sequence between FRT GS1-1 and FRT GS1-2. After recombina-
tion, one of the resulted FRT sequences bears mutations in both
50 and 30 arms to stop further recombination. Thus, exon 2 will
be flipped back and gene function will be restored (Supporting
Information Fig. S2). We named this system as COSIEN.
Linearized targeting vector was electroporated into 1.6 ×
107 clones A3 of UG347 ES cells, which we established from
129SvEv blastocysts. Three hundred G418-resistant ES cell clones
were initially screened by Southern blot and targeted ES cell
clones were identified (Supporting Information Fig. S10A). The
targeted ES clones were injected into blastocysts from C57BL/6
albino mice. The resulting chimeras were bred to C57BL/6
females and F1 agouti offspring were genotyped by Southern
analyses. Three targeted clones were used for injection and
one of them underwent germline transmission. Subsequently,
mice heterozygous for Tak1 floxed-FRTed allele (Tak1fl-frt/wt;
Supporting Information Fig. S10B) were intercrossed to obtain
homozygous mice for Tak1 floxed-FRTed allele (Tak1fl-frt/fl-frt).
The homozygous mice were obtained as an expected ratio
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(25%, n > 100), suggesting that presence of the loxP, FRT, and
the neo cassette does not influence gene activity.
When bred with a germline deleter Cre strain Meox2-Cre,
all mice positive for the Cre showed a flipped band by genomic
PCR (Supporting Information Fig. S10C). After segregation of
Cre from the flipped Tak1 allele (designated as Tak1fc allele,
Tak1fc/+ mice were bred with Meox2-Cre mice again. None of
the Tak1fc/+ mice carrying Cre showed the floxed band (200 bp)
with Tak1 G1/G2 primers indicating that the Cre-mediate DNA
inversion occurs only one time (n > 20, data not shown). Homo-
zygous mice for Tak1 Cre-flipped allele (Tak1fc/fc) were gener-
ated by intercross of Tak1fc/+ mice and resulted homozygous
mice showed embryonic lethality around E9.5 similar to the Tak1
homozygous null embryos reported earlier (data not shown).
These suggesting that the Tak1 floxed-FRTed allele can flip one
time with Cre recombinase to disrupt gene function.
When bred with Flipper mice (carrying FLPe gene) [32], mice
carrying both the Tak1fx-frt alleles and Flpe showed a flipped
band by genomic PCR using TAK1 F6/G2 primers (Supporting
Information Fig. S10D). Unlike the case of Meox2-Cre, we found
some of them showed both floxed and flipped bands suggesting
that DNA inversion mediated by FLPe may be less efficient than
that by Cre (Supporting Information Fig. S10D, sample #4).
Injury Models
All mice received presurgical analgesia consisting of 0.1 mg/kg
buprenorphine, followed by anesthesia with inhaled isoflurane,
and close postoperative monitoring with analgesic administra-
tion. Experimental trauma model 1: burn/tenotomy (B/T) mice
received a 30% total body surface area (TBSA) partial-thickness
burn on the shaved dorsum followed by left hind limb Achilles’
tendon transection [16]. The dorsum was burned using a
metal block heated to 60C and applied to the dorsum for
18 seconds continuously. The tenotomy site was closed with a
single 5-0 vicryl suture placed through the skin only. Ub.Cre/
Tak1fl-frt/fl-frt and littermate control mice received 175 mg/kg
tamoxifen 7 and 3 days prior the surgery and 7, 14, and
21 days after the B/T surgery. Experimental trauma model 2:
critical-sized (4-mm) calvarial defects were created in Tak1fl-frt/fl-frt
mice to assess TAK1 in bone healing with local injection of either
(a) control adenovirus (Ad.control; 9 × 1010 plaque-forming unit
(PFU) per injection site for 9 weeks); (b) Cre adenovirus (Ad.cre;
1.6 × 1011 PFU per injection site for 9 weeks), or (c) Cre/Flp
(1 × 1010 PFU per injection site) virus (Ad.cre for every 3 days
for 12 days followed by reconstitution of TAK1 expression with
Ad.Flp for 8 weeks). Respective adenoviruses were injected into
the calvarial defects.
In Vivo Drug Treatment: NG-25, TAK1 Inhibitor
C57BL/6 mice underwent burn/tenotomy as described above.
Following injury mice received either phosphate-buffered saline
vehicle control or TAK1 inhibitor (2 mg/kg) in 500 μl via intraper-
itoneal injection. Mice in both groups were euthanized at 3- and
9-weeks after injury for further analysis. Each group had n ≥ 3
animals.
Cell Harvest
Mesenchymal cells, local tissue, and osteoblasts from Tak1fl-frt/fl-frt,
and corresponding littermate controls were harvested from
(a) the inguinal fat pad (adipose-derived stem cells [ASCs]),
(b) from the Achilles’ tendon (tendon-derived cells; TdCs), and
(c) from femur, tibia, and fibula (osteoblasts). All tissue was
mechanically minced, digested with collagenase A and dispase.
Cells were separated via 100 μm cell strainer and digestive
enzyme were quenched in standard growth medium (Dulbecco’s
modified Eagle’s medium [DMEM] supplemented with 10% fetal
bovine serum [FBS] and 1% penicillin/streptomycin). Cells were
spun down at 1,000 rpm for 5 minutes. The supernatant was dis-
carded, and the cell pellet was resuspended in standard growth
media and subsequently plated. Isolation of adipose and bone-
marrow derived mesenchymal cells in this manner has previously
been validated as demonstrating trilineage differentiation consis-
tent with mesenchymal stem cells [36–39].
Cell Culture and Transfection
Cells were grown in standard growth medium (DMEM supple-
mented with 10% FBS and 1% penicillin/streptomycin). Cells used
were all passage 2 through 6. Tak1fl-frt/fl-frt cells were treated with
either Ad.LacZ (MOI 500), Ad. Cre (MOI 500) in DMEM free of
FBS (serum deprived) for 24 hours. Cells were then cultured in
standard growth media (serum-replete) for 48 hours. Subsequent
transfection was then performed with either Ad.LacZ, Ad.Cre, or
Ad. FLP (MOI 500). As with the initial transfection, second trans-
fection was performed in DMEM free of FBS for 24 hours before
being transitioned to standard growth media for 48 hours. At this
point, cells were ready for RNA/protein harvest or for use in pro-
liferation and differentiation assays.
Flow Cytometric Preparation and Confirmation of
Purity
Adipose-derived stem cells were harvested as above and sus-
pended in Hanks’ balanced saline solution (HBSS) prior to filtration
through a 70-μm sterile strainer and centrifuged at 800 rpm for
5 minutes before removing the supernatant and washing in HBSS.
This process was repeated three times before incubation with
fluorescently labeled antibodies. AmCyan viability dye used as a
marker to gate for live versus dead cells. Lineage defined by the
following myeloid markers CD45-PE; MHCII-PE; B220-PE; CD11b-
FITC; CD34-FITC (eBioscience, Torrey Pines, CA; Thermo Fisher,
Waltham, MA). Following 1 hour of incubation at 4C, sample
were washed and filtered through a 45-μm mesh filter before
being run on a FACSAria II (BD Biosciences) Cell Sorter at the Uni-
versity of Michigan Flow Cytometry Core in the Biomedical Sci-
ence Research Center. Samples were gated to separate debris
and autofluorescent signals from the cell population. Data were
then analyzed using the FlowJo Software (TreeStar). Flow cyto-
metric data was normalized to account for differences in aggre-
gate number between cell types.
siRNA Treatment. To generate TAK1 knockdown cells, ASCs
and tendon-derived cells (TdCs) were transfected with siRNA
(s77092, s77094, and negative control no. 1, Ambion) using
Lipofectamine RNAiMAX transfection reagent (Thermo). For
cell proliferation assays, siRNAs were transfected when cells
were plated after 3–4 hours and the medium was changed.
For cell differentiation assays, siRNAs were transfected when
the medium was changed to osteogenic differentiation media
(ODM) and every 2 days.
Proliferation Assays
Cells were seeded in 12-well plates at a density of 5 × 103 cells
per well (n = 3). Cells were grown in standard growth medium
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(DMEM supplemented with 10% FBS and 1% penicillin/strepto-
mycin). Treatment groups had their media supplemented as
follows: NG-25 (4 μM NG-25/DMSO in DMEM; 5Z-O) 1 μM
5Z-O/DMSO in DMEM. Media changed every 3 days. At 12, 24,
48, 72, and 96 or 144 hours cells were lifted following trypsin–
EDTA treatment and were manually enumerated using trypan
blue stain and a hemocytometer. Additionally, cell proliferation
was assessed by bromodeoxyuridine (BrdU) incorporation.
Differentiation Assays
Cells were seeded in 12-well plates at a density of 3 × 103 cells
per well (n = 3). Prior to differentiation cells were maintained in
standard growth media (DMEM supplemented with 10% FBS
and 1% penicillin/streptomycin). Differentiation was performed
in ODM (DMEM supplemented with 10% FBS, 1% penicillin/
streptomycin, 10 mM β-glycerophosphate, and 100 μg/ml ascor-
bic acid). ODM media in isolation was used for control groups.
The NG-25 test group was treated with 4 μM NG-25/DMSO in
ODM. Differentiation media were changed every 3 days. Cells for
early RNA or protein quantification were collected after 3 days of
differentiation. Early functional osteogenic differentiation was
assessed by ALP stain and quantification of ALP enzymatic activ-
ity after 7 days. Alizarin red staining for bone mineral deposition
and colorimetric quantification was completed at 14 days.
MicroCT Analysis
MicroCT scans (Siemens Inveon using 80 kVp, 80 mA, and
1,100-millisecond exposure) were used to quantify: HO volume
in mice with burn/tenotomy. Images were reconstructed and
HO volume quantified using a calibrated imaging protocol as
previously described with the MicroView μCT viewer (Parallax
Innovations, Ilderton, Canada) [14]. The calculation of the thresh-
old for regenerating calvarial bone was performed in MicroView
and determined equivalent to 800 Houndsfield Units. Percentage
healing on the parietal bone containing the defect was deter-
mined by dividing the rest-defect area by the mean of the defect
size at day 1 after surgery. TAK1 mice were scanned at 24 hours
and 9 weeks after surgery.
Preparation of Tissue for Histology
Histologic evaluation was performed at indicated time points
in hind limbs of burn/tenotomy mice (wild-type, tmKO and
respective littermate controls) and calvarial defects of Tak1fl-frt/fl-frt
mice. Hind limbs and calvaria were fixed in formalin overnight
at 4C and subsequently decalcified in 19% EDTA solution for
3–5 weeks at 4C until x-ray verification of decalcification. Hind
limbs were embedded in paraffin, and 5–7 μm sections were
cut and mounted on Superfrost Plus slides (Fisherbrand,
Hampton, NH) and stored at room temperature.
Histology and Immunostaining
Hematoxylin and eosin (H&E) and Movat’s pentachrome staining
were performed of the ankle region and calvaria, respectively.
Immunostaining of extraskeletal ectopic bone was performed on
rehydrated wax sections with the following primary antibodies:
rabbit anti-PDGFR (antibody sc-338, Santa Cruz Biotechnology,
Dallas, TX), mouse anti-PDGFR (antibody sc-398206, Santa Cruz
Biotechnology) goat anti-Sox9 (antibody sc-17341, Santa Cruz Bio-
technology), rabbit anti-Ki67 (antibody AB9260, Millipore, Darmstadt,
Germany), goat anti-mouse anti-pSmad1/5 (antibody sc-12353, Santa
Cruz Biotechnology), polyclonal rabbit anti-TAK1 (NB100-56363, Novus
Biologicals, Littleton, CO), rabbit anti-pTAK1 (antibody sc-4508,
Cell Signaling, Danvers, MA), goat anti-pSmad1/5/8 (antibody
sc-12353, Santa Cruz Biotechnology), rabbit anti-pSmad 2/3
(antibody sc-11769 Santa Cruz Biotechnology), rabbit anti-
pTAK1 (antibody NBP1-9609, Novus Biologicals, Littleton, CO),
rabbit anti-pp38 (antibody sc-9211, Cell Signaling). Appropriate
dilutions were determined before achieving final images. The
appropriate fluorescent secondary antibody was applied and
visualized using fluorescent microscopy. Secondary antibodies
consisted of anti-rabbit or anti-goat Alexafluor-488 (green) or
Alexafluor-594 (red; A21206, A11055, A21207, A11058, Life
Technologies).
Quantification of Calvarial Defect Healing
Histomorphometric measurements to quantify the area of regen-
erate bone were performed using ImageJ on every 10th Aniline
Blue stained slide of the defect (Ad.LacZ: six defects, 118 total
images; Ad.Cre: six defects, 120 total images; Ad.Cre/Ad.Flp: eight
defects, 120 total images). Regenerative bone was manually
selected and isolated from each section and the area calculated
using the measure function on ImageJ. For each defect, measured
areas were summed to estimate total new bone formation.
Microscopy
All fluorescently stained images were taken using an Olympus
BX-51 upright light microscope equipped with standard DAPI,
488 nm, and TRITC cubes attached to an Olympus DP-70 high
resolution digital camera. Each site was imaged in all channels
and overlaid in DPViewer before examination in Adobe Photo-
shop. H&E, safranin O, pentachrome, and aniline blue sections
were imaged at ×10 and ×20 magnification. Immunofluores-
cent images were taken at either ×20 or ×40 magnification.
Immunocytochemical images were taken at ×60 and ×100
magnification under oil. Scale bars were placed for all images
with a standard 200 μm diameter.
Western Blot Analysis
Tissue/cells were lysed with RIPA lysis buffer (Santa Cruz Bio-
technology) containing protease inhibitors, 1 nM sodium orthova-
nadate, 1 mM PMSF. The protein concentration was determined
using the BCA Plus protein assay kit (Pierce, Rockford, IL). SDS-
PAGE was used to separate the protein extract (40 μg). After
transfer to a polyvinylidene fluoride membrane (EMD, Millipore,
Darmstadt Germany), and blocking with 5% milk in TBS with
0.1% Tween-20 (TBST) for 1 hour, then incubated overnight with
the following antibodies at 4C: rabbit anti-pTak1 (antibody sc-
9339, Cell Signaling), rabbit anti-TAK1 (NB100-56363, Novus Bio-
logicals, Littleton, CO), rabbit anti-pSmad1/5/8 (antibody 9516,
Cell Signaling), rabbit anti-Smad2/3 (antibody sc-3102, Cell Signal-
ing), rabbit anti-pp38 (antibody 9211, Cell Signaling), rabbit anti-
PCNA (antibody 2586, Cell Signaling), and rabbit anti-α-tubulin
(antibody 2144, Cell Signaling). After washing with TBST five
times, the membrane was incubated with appropriate Horseradish
peroxidase (HRP)-conjugated secondary antibody (antibody 7074,
Cell Signaling) for 30 minutes at room temperature and detected
using chemiluminescence PICO substrate (Pierce, Rockford, IL).
Gene Analysis
To assess the recombination efficiency of the floxed Tak1 locus
(exon 2) and gene expression in the total RNAs were isolated from
AdMSCs transfected with Ad.LacZ, Ad.Cre, Ad.FLP, and Ad.Cre/Ad.
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FLP (RNeasy Mini Kit; Qiagen, Germantown, MD) per manufac-
turer’s specifications, and 1 μg RNA using High capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City, CA)
according to manufacturer’s protocols. Quantitative real-time
PCR was carried out using the Applied Biosystems Prism 7900HT
Sequence Detection System and SybrGreen PCR Master Mix
(Applied Biosystems, Beverly, MA). Specific primers for these
genes were:
Tak1 Forward: GGTTGTCGGAAGAGGAGCTTTT
Tak1 Reverse: AACTGCCGGAGCTCCACAAT
Gapdh Forward: TCTCCTGCGACTTCAACAGCAA
Gapdh Reverse: CCCACATACCAGGAAATGAGCTTG
Alp Forward: TCTGCCTTGCCTGTATCTGGAATC
Alp Reverse: GTGCTTTGGGAATCTGTGCAGTCT
Runx2 Forward: CACCGAGACCAACCGAGTCATTTA
Runx2 Reverse: AAGAGGCTGTTTGACGCCATAG
Sox9 Forward: GGAGGAAGTCGGTGAAGAAC
Sox9 Reverse: AGCGCCTTGAAGATAGCATT
The PCR protocol included a 95C denaturation (20 seconds),
annealing (20 seconds), and 72C extension (30 seconds).
Detection of the fluorescent product was carried out at the
end of the 72C extension period. Each sample was tested at
least in triplicate and repeated for three independent cell/tissue
preparations.
Statistical Analysis
Means and SDs were calculated from numerical data, as pre-
sented in the text, figures, and figure legends. In figures, bar
graphs represent mean, whereas error bars represent 1 SD. Sta-
tistical analysis was performed using a Student’s t test to directly
compare two groups. p-Values are included in figure legends.
Figure 1. Transforming growth factor-β activated kinase 1 (TAK1) signaling mediates pathologic wound healing after musculoskeletal injury.
(A): Mouse model of musculoskeletal injury with hind limb tenotomy and dorsal 30% total body surface area burn injury—tenotomy at mid-
point of Achilles’ tendon; burn ipsilateral to tenotomy. Histologic sections are collected from region between tibial midpoint and calcaneus at
the site of highest chondrogenic and osteogenic differentiation. (B): Representative three-dimensional reconstruction (9 weeks) and H&E
(3 weeks) demonstrating localization of heterotopic ossification. (C): Gene set enrichment analysis demonstrates upregulation of TAK1 signal-
ing at the tendon transection site 3 weeks after injury (Enrichment Score = 0.88, FDR < 0.001). (D): Expression of TAK1 in the uninjured and
injured hind limb—expression of TAK1 highest at areas undergoing early chondrogenic differentiation. (E): Expression of pp38 in the unin-
jured and injured hind limb—expression of pp38 highest in area undergoing early chondrogenic differentiation. (F): Expression of pSMAD2/3
in the uninjured and injured hind limb—expression of pSMAD2/3 highest in areas of mesenchymal condensation adjacent to areas of chon-
drogenic differentiation. Histology at 3 weeks after injury; ×40 magnification. Scale bars = 200 μm.
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RESULTS
TAK1 Signaling Mediates Pathologic Wound Healing
After Musculoskeletal Injury
To study aberrant wound healing, we used a model of tHO
consisting of hind limb Achilles’ tendon transection with dorsal
burn injury (Fig. 1A, 1B) [16]. Gene set enrichment analysis of
RNA sequencing data from hind limb tissue samples obtained
from mice 3 weeks after injury identified upregulation of the
TAK1 pathway when compared with the uninjured hind limb
(Enrichment Score [ES] = 0.88, False discovery rate (FDR) < 0.001;
Fig. 1C). Immunostaining also confirmed upregulation of TAK1
protein expression at the injury site 3 weeks after injury (Fig. 1D),
and importantly upregulation of phosphorylated proteins down-
stream in the TAK1 pathway including pp38 and pSMAD 2/3
(Fig. 1E, 1F). Previous studies have shown that TAK1, an intracel-
lular mediator of TGF-β and BMP signaling, plays a key role in nor-
mal postnatal endochondral ossification [24–26], making it a
potential target to eliminate HO.
We first developed a mouse allowing targeted deactivation
and reactivation of Tak1 (Takfx-frt/fx-frt; Supporting Information
Fig. S2) and confirmed that genetic loss of Tak1 by tamoxifen
inducible Ubiqutin-CreER (Ub.CreERT) significantly reduces
tHO radiographically and histologically (Fig. 2A, 2C; Support-
ing Information Fig. S3A). Systemic treatment of wild-type
mice with NG-25, a TAK1 inhibitor, which occupies the ATP
binding pocket of TAK1 [33], significantly reduced tHO volume
(Fig. 2D, 2E; Supporting Information Fig. S3B) and decreased car-
tilage presence 3 weeks after injury (Fig. 2F). Correspondingly,
treatment with NG-25 reduced pSMAD 1/5, pSMAD 2/3, and
SOX9 expression on immunostaining (Supporting Information
Fig. S4A–S4C). These findings indicate that genetic or pharmaco-
logic loss of TAK1 reduced pathologic wound healing, providing a
novel target for therapeutic intervention.
Genetic Loss of Tak1 Within Mesenchymal Cells
Alters Cellular Proliferation and Differentiation
to Prevent tHO
We have previously shown that Prx-Cre expressing cells, mes-
enchymal progenitors, contribute to tHO [14] induced by hind
limb Achilles’ tendon transection with dorsal burn injury. Because
immunostaining of tissue from the injury site indicated that TAK1
signaling is present in MSCs (Fig. 3A) we generated a Tak1 condi-
tional knockout mouse for MSCs (Tak1 cKO; Prxcre/Tak1fx-frt/fx-frt).
Histologic analysis demonstrated little-to-no evidence of cartilage,
compared with our Wild Type (WT) control (Fig. 3B). Immunos-
taining confirmed reduction of pTAK1 at the injury site of these
mice (Fig. 3C). Interestingly, when compared with littermate con-
trols, Tak1 cKO mice had increased cellular proportion of K67+
cells at the injury site (Fig. 3D).
Figure 2. Transforming growth factor-β activated kinase 1 (TAK1) signaling is associated with heterotopic ossification after musculoskele-
tal injury. (A): Three-dimensional (3D) microCT reconstruction of Tak1 tmKO (tamoxifen-inducible postnatal Tak1 knockout [Tak1tmKO:
Ub.CreERT/Tak1fx-frt/fx-frt]) and littermate control hind limbs showing heterotopic bone 9 weeks after injury (red circles around heterotopic
ossification), tamoxifen was injected 7 and 3 days before injury and 3 days after injury. (B): Quantification of heterotopic bone volume in
Tak1 tmKO and littermate control hind limbs showing heterotopic bone 9 weeks after injury (1.0 versus 0.29, p < .05); (C): Safranin O
staining (red stain) in Tak1 tmKO and littermate control hind limbs showing cartilage 3 weeks after injury (×4 magnification; dotted box
indicates site of magnified image in right bottom corner). (D): 3D microCT reconstruction of NG-25 and treatment control hind limbs
showing heterotopic bone 9 weeks after injury. (E): Quantification of heterotopic bone volume in NG-25 and treatment control hind limbs
showing heterotopic bone 9 weeks after injury (1.0 versus 0.35, p < .05). (F): Safranin O staining (red) in NG-25 and treatment control
hind limbs showing cartilage 3 weeks after injury (×4 magnification; dotted box indicates site of magnified image in right bottom corner).
All scale bars = 200 μm; n ≥ 5 for all quantifications; *, p < .05.
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Consistent with these findings and previously published
results, MSCs isolated from adipose tissues of Tak1fx-frt/fx-frt
mice (Supporting Information Fig. S5A–S5C) exhibited markedly
reduced in vitro osteogenic and chondrogenic differentiation
upon treatment with adenovirus Cre (Ad.Cre) when compared
with adenovirus control (Ad.LacZ; Supporting Information
Fig. S6A–S6E). Additionally, Tak1fx-frt/fx-frt MSCs treated with
Ad.Cre exhibited increased proliferation when compared with
Tak1fx-frt/fx-frt MSCs treated with Ad.LacZ (Fig. 4A, 4B). NG-25
also reduced osteogenic differentiation and chondrogenic differ-
entiation of MSCs in vitro (Supporting Information Fig. S7A–
S7F). In contrast, NG-25-treated MSCs demonstrated reduced
proliferation when compared with vehicle control-treated cells
(Fig. 4C, 4D). Similarly, 5Z-7-oxozeaenol (5Z-O) [33], a potent
ATP competitive irreversible inhibitor of TAK1 significantly
reduced proliferation when compared with vehicle control-
treated cells (Supporting Information Fig. S8A, S8B). The reduc-
tion in cell proliferation observed with currently developed
TAK1 inhibitors may be due to their off target effects including
inhibition of Abelson tyrosine kinase (ABL), an essential mole-
cule that regulates cell proliferation [33]. To test this, we
developed a system to silence Tak1 with multiple siRNAs
(Fig. 4E; Supporting Information Fig. S9A, S9B). Utilizing these
specific siRNAs we found a similar increase in cell proliferation by
BrdU assay and cell counting (Fig. 4F, 4G). Treatment with siRNA,
similar to Tak1 knockout with our mouse model, decreased
in vitro osteogenic differentiation by alkaline phosphatase (ALP)
and alizarin red (Fig. 4H). Overall, these findings suggest that cur-
rent pharmacologic inhibitors of TAK1 are unable to phenocopy
genetic loss of Tak1 in the setting of tissue injury, indicating the
need for more specific TAK1 inhibitors.
In Vitro Validation of a Novel Dual-Inducible Model to
Knockout and Rescue Tak1 Signaling Using COSIEN
The important finding that loss of Tak1 upregulates prolifera-
tion led us to consider whether this property can be used to
improve tissue regeneration. Typically, studies using pharmaco-
logic agents to improve tissue regeneration have focused on
the effects of these mediators during the “drug on” period.
Interestingly, implicit in studies evaluating regenerative thera-
pies is a period during which drug is not present within the
organism—this “drug off” period may be in between doses or
following completion of agent administration. The role of
the “drug off” period, which proliferating cells may be able
to undergo differentiation, has gone largely unrecognized in
tissue regeneration. Therefore, because TAK1 is required for
Figure 3. Genetic loss of transforming growth factor-β activated kinase 1 (TAK1) signaling in mesenchymal cells increases cell prolifera-
tion and impairs chondrogenic differentiation to prevent trauma-induced heterotopic ossification. (A): Coexpression of pTAK1
and PDGFRα+ in the injured and uninjured hind limb 3 weeks after injury (×20 magnification; top left corner: pTAK1—green overlay
with PDGFRα—red; bottom right corner: pTAK1—green overlay with PDGFRα—red and DAPI—blue). (B): Pentachrome of injury site of
Prx-cre/Tak1fx-frt/fx-frt and littermate control mice 3 weeks after injury (×10 magnification; Alcian blue represents cartilaginous tissue; red
box shows areas of immunostaining). (C): Immunostaining for pTAK1 at the injury site of Prx-cre/Tak1fx-frt/fx-frt and littermate control mice
3 weeks after injury (×10 magnification; right side: pTAK1—green overlay with DAPI—blue). (D): Immunostaining for Ki67 at the injury site
of Prx-cre/Tak1fx-frt/fx-frt and littermate control mice 3 weeks after injury (×10 magnification; right side: Ki67—green overlay with DAPI—
blue). All scale bars = 200 μm.
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cell differentiation and extracellular matrix (ECM) production
[23, 24, 26], we sought to determine whether TAK1 could be
modulated to improve regeneration of tissues through a coordi-
nated approach of TAK1 inhibition (proliferation) and subse-
quent reactivation (differentiation).
Based on our findings, we determined that current phar-
macologic inhibitors of TAK1, like many pathway directed
therapies, are not specific enough to provide insight into a
“drug on”/“drug off” strategy to improve tissue healing. We
decided to mimic this approach taking advantage of an
important design aspect of the Tak1fx-frt/fx-frt mouse—in par-
ticular, this is a novel dual inducible Cre/Flp mouse model
allowing for loss of gene function (Cre/lox) followed by res-
cue (Flp/Frt). We have named this the COSIEN mouse, as the
targeted gene segment is initially inverted or “gene off” by
Cre and then subsequently reinverted or “gene on” by Flp.
Mutations were introduced into the Lox and Frt recognition
sites to allow only one-time inversion (Cre) and reversion
(Flp) of the targeted gene segment (Fig. 5A). This model was
then validated genotypically in live animals (Supporting
Information Fig. S10A–S10D). Although dual inducible models
have been reported before to control temporal knockout of
separate genes in neural development and tumor models
[34–36], to the best of our knowledge, use of a dual inducible
approach to inactivate and subsequently reactivate gene activ-
ity has not been described. This ability to optimize gene dis-
ruption and reactivation in a timed fashion would allow
therapeutic optimization for developmental and post-traumatic
pathologies.
MSCs isolated from Tak1fx-frt/fx-frt mice showed reduced
Tak1 mRNA expression with Ad.Cre, which was subsequently
rescued after Ad.Flp treatment (Fig. 5B). Protein level expres-
sion of pTAK1, pp38, pSMAD 1/5, and pSMAD 2/3 were
reduced with Ad.Cre but increased with subsequent Ad.Flp
treatment (Ad.Cre/Ad.Flp; Fig. 5C–5G). As expected, genetic
loss of Tak1 (Ad.Cre) reduced osteogenic differentiation while
subsequent rescue of Tak1 (Ad.Cre/Ad.Flp) improved osteo-
genic differentiation relative to Ad.LacZ treatment (Supporting
Information Fig. S11A, S11B). Taken together, these findings
confirm that the COSIEN mouse provides an approach to study
“drug on” (Ad.Cre) and “drug off” (Ad.Flp) with specificity
for Tak1.
Figure 4. Comparison of pharmacologic and genetic transforming growth factor-β activated kinase 1 (TAK1) inhibition. (A): Cell prolifera-
tion (BrDU) of Ad.Cre and Ad.LacZ treated Tak1fx-frt/fx-frt adipose-derived stem cells (ASCs). (B): Cell proliferation (cell counting) of Ad.Cre
and Ad.LacZ treated Tak1fx-frt/fx-frt ASCs. (C): Cell proliferation (BrDU) of ASCs treated with NG-25. (D): Cell proliferation (cell counting) of
ASCs treated with NG-25. (E): ASCs were transfected with siRNAs for TAK1, and TAK1 expression level was analyzed by qPCR. (F): Cell
counting showing that siRNAs for TAK1 transfection significantly promote cell proliferation in vitro. (G): BrDU proliferation assay showing
that siRNAs for TAK1 transfection significantly promote cell proliferation in vitro (left: ASCs and right: tendon-derived cells [TdCs]). (H):
Osteoblastic differentiation assay showing that siRNAs for TAK1 transfection significantly suppressed the differentiation in vitro (upper:
ALP stained TdCs at day 5 and lower: alizarin red stained TdCs at day 12). *, #, p < .05; ##, p < .01. Student’s t test (*, scramble versus
siRNA-1; #, scramble versus siRNA-2).
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Improved Bone Regeneration with Dual-Inducible
Model to Evaluate “Drug on” and “Drug off”
Therapeutic Strategy Targeting TAK1
After validating the COSIEN model in vitro, we next studied its
effect in vivo using a critical-size calvarial defect model. Calvarial
defects are often used for the study of bone healing; although
most studies describing critical-size calvarial defects use scaffolds
impregnated with MSCs or growth factors, these approaches
may be difficult to translate clinically. To validate the COSIEN
model in vivo and to demonstrate that a regenerative medicine
strategy emphasizing both the “drug on” and “drug off” periods
of therapy could improve wound healing, we injected mice with
either Ad.LacZ only, Ad.Cre only, or Ad.Cre followed by Ad.Flp
(Ad.Cre/Ad.Flp), directly into the calvarial defect area for 9 weeks
(Fig. 6A). For the third regimen, Ad.Flp was started to inject from
the second week. As expected, mice treated with Ad.Cre/Ad.Flp
had significantly more osteoid deposition on the basis of microCT
(Fig. 6B) and histologically with aniline blue quantification (Fig. 6C,
6D). The Ad.Cre group developed similar amount of tissues with
the Ad/Cre/Ad.Flp group, but osteoid formation remained similar
to the control group (Fig. 6C, 6D). Calvarial samples obtained from
Tak1fx-frt/fx-frt mice showed reduced Tak1 mRNA expression with
Ad.Cre, which was subsequently restored after Ad.Flp treatment
(Fig. 6E).
Levels of pTAK1, pSMAD 1/5, and pSMAD 2/3 from these sam-
ples were found reduced in the Ad.Cre group but increased with
subsequent Ad.Flp treatment (Ad.Cre/Ad.Flp group; Fig. 7A–7D).
Immunostaining confirmed a decrease of TAK1 (Ad.Cre) with
subsequent rescue of TAK1 (Ad.Cre/Ad.Flp; Fig. 7E) and also
increased presence of MSCs (PDGFRα+) in both the Ad.Cre and
Ad.Cre/Ad.Flp groups (Fig. 7F). Immunostaining for pSMAD2/3
was consistent with immunoblot results (Supporting Information
Fig. S12). Proliferation observed by Ki67 was increased in the
Ad.Cre versus Ad.LacZ group, with restoration of normal pat-
tern on Ad.Flp administration (Fig. 7G). This was confirmed
Figure 5. In vitro validation of a dual-inducible model to knockout and rescue transforming growth factor-β activated kinase 1 (TAK1) signal-
ing using COmbinational Sequential Inversion ENgineering. (A): Schematic for dual-inducible model within the Tak1fx-frt/fx-frt mouse: mutations
are introduced into the Lox and Frt sites to allow only one-time inversion and reversion of the targeted gene segment. Initial inversion (loss
of gene function) is driven by a Cre/Lox system following addition of Ad.Cre. Rescue reversion (return of gene function) is driven by a Flp/Frt
system following addition of Ad.Flp. (B): Normalized quantification of Tak1 gene expression from Ad.LacZ, Ad.Cre, and Ad.Cre + Ad.Flp treated
mesenchymal cells (Ad.LacZ: 1.0; Ad.Cre: 0.41; Ad.Cre + Ad.Flp: 0.55). (C): Representative immunoblot of Ad.LacZ, Ad.Cre, and Ad.Cre + Ad.Flp
treated mesenchymal cells for pTAK1, pSMAD 1/5, pp38, pSMAD 2/3, and α-tubulin. (D): Normalized quantification of pTAK1 protein expres-
sion from Ad.LacZ, Ad.Cre, and Ad.Cre + Ad.Flp treated mesenchymal cells (Ad.LacZ: 1.0; Ad.Cre: 0.66; Ad.Cre + Ad.Flp: 1.2). (E): Normalized
quantification of pp38 protein expression from Ad.LacZ, Ad.Cre, and Ad.Cre + Ad.Flp treated mesenchymal cells (Ad.LacZ: 1.0; Ad.Cre: 0.65;
Ad.Cre + Ad.Flp: 0.88). (F): Normalized quantification of pSMAD1/5 protein expression from Ad.LacZ, Ad.Cre, and Ad.Cre + Ad.Flp treated mes-
enchymal cells (Ad.LacZ: 1.0; Ad.Cre: 0.87; Ad.Cre + Ad.Flp: 2.25). (G): Normalized quantification of pSMAD 2/3 protein expression from Ad.
LacZ, Ad.Cre, and Ad.Cre + Ad.Flp treated mesenchymal cells (Ad.LacZ: 1.0; Ad.Cre: 0.02; Ad.Cre + Ad.Flp: 4.81). All cells were treated with
Ad.Cre (or Ad.LacZ) for 24 hours under serum deprivation conditions followed by 48 hours in serum replete and subsequently treated with
Ad.LacZ (Ad.LacZ group), Ad.Cre (Ad.Cre group), or Ad.Flp (Ad.Cre + Ad.Flp) for 24 hours in serum deprived conditions followed by culture for
an additional 2 days in serum replete conditions. Mesenchymal cells described are adipose-derived stem cells; *, p < .05.
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with immunoblotting for PCNA in protein obtained from Ad.
LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvaria (Supporting
Information Fig. S13A, S13B).
DISCUSSION
tHO is a clinical phenomenon which occurs in patients following
severe trauma, and is characterized by the development of
extraskeletal bone in soft tissues. Our findings indicate that
TAK1 can be targeted pharmacologically to prevent tHO. We
then use this model of pathologic wound healing to elucidate a
critical aspect of therapeutic regimens—the contribution of the
“drug on” and the “drug off” state to therapeutic impact. Taken
together, our findings using the COSIEN mouse (Tak1fx-frt/fx-frt)
suggest that a coordinated “drug on” and “drug off” strategy
may be critical for pharmacologic improvement of tissue regen-
eration, thereby transforming the paradigm of regenerative
medicine. Although current studies focus primarily on the “drug
on” state, implicit in these treatment strategies is a “drug off”
state, which also contributes to healing. The dual inducible
approach may allow for validation of gene targets considering
both the “drug on” and “drug off” effects prior to pharmaco-
logic development in the context of wound healing.
Patients with tHO are faced with debilitating pain, nonheal-
ing wounds, and joint contractures limiting function [17, 18, 37].
We have previously shown that tHO forms via endochondral
ossification, and that inhibition of hypoxic signaling reduces tHO
through its effects on cartilage production [14]. We focused on
TAK1 signaling due to the prominent role of TGF-β signaling dur-
ing normal cartilage development [20–26]. Mice with genetic
loss of Tak1 driven by the Col2 or Prx promoters (Col2-cre or
Prx-cre) exhibit impaired cartilage formation and loss of second-
ary ossification centers [25]. In this study, we found that mice
with tamoxifen-inducible systemic loss of Tak1 exhibit
Figure 6. Improved regeneration with Cre/Flp dual inducible mouse model to simulate “drug on” and “drug off” therapeutic strategy
targeting transforming growth factor-β activated kinase 1 (TAK1) signaling. (A): Calvarial defect schematic with Ad.LacZ, Ad.Cre, or Ad.
Cre/Ad.Flp. (B): Representative microCT scans showing healing of Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvarial defects at 9 weeks
with corresponding baseline scans at day 1. (C): Representative aniline blue staining of the calvarial defect site 9 weeks after injury
(dashed black box marks defect site). (D): Normalized quantification of osteoid in Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvarial
defects 9 weeks after injury (Ad.LacZ: 1.0; Ad.Cre: 1.14; Ad.Cre/Ad.Flp: 2.23). (E): Normalized quantification of Tak1 gene expression from
Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvarial defects (Ad.LacZ: 1.0; Ad.Cre: 0.33; Ad.Cre/Ad.Flp: 0.76). In experimental groups,
defects were treated with Ad.Cre every 3 days starting from the day of surgery until day 12; at day 12, defects were treated with either
Ad.Cre (Ad.Cre group) or Ad.Flp (Ad.Cre/Ad.Flp group); in control group, defects were treated with Ad.LacZ every 3 days. Cells for protein
extraction collected by harvest of the calvarial defect after removal of dura; *, p < .05.
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significantly reduced levels of tHO, consistent with the role of
TAK1 in the development of ossification centers. Because tHO
forms through an inflammatory stimulus (e.g., trauma), we sub-
sequently focused on genetic loss of Tak1 only in the mesenchy-
mal cells which contribute directly to the developing ectopic
anlagen of tHO using the Prx promoter (Prx-cre) [14]; indeed,
we found that in vivo genetic loss of Tak1 in mesenchymal cells
is sufficient to eliminate tHO. Use of the pharmacologic agent
NG-25 to inhibit TAK1 confirmed an approach targeting TAK1
to prevent tHO. As expected, in vitro experiments confirmed
that genetic loss of Tak1 or treatment with NG-25 reduced
chondrogenic differentiation. However, while NG-25 and 5Z-O,
another pharmacologic TAK1 inhibitor, reduced mesenchymal
cell proliferation in vitro, genetic loss of Tak1 increased cellular
proliferation. These findings may be attributed to off-target
effects of TAK1 inhibitors such as NG-25 which also inhibit
other kinases including epidermal growth factor receptor and
ABL [33]. These findings also indicate that improved TAK1
inhibitors are required to achieve the therapeutic potential,
which is highly encouraged by our genetic data.
Initially, we designed the dual-recombinase mouse model
to examine whether a single gene could be targeted to knock-
out and subsequently reactivate the gene of interest. Several
previous studies have combined Cre/lox and Flp/Frt technologies
to generate dual-inducible mouse models, these have been used
to target different genes [33, 34]. Therefore, these technologies
have been used to temporally control different genes. The LoxP-
FRT Trap (LOFT) method has been reported to disrupt a floxed
copy of a gene and subsequently reactivate another copy of the
same gene that has been inactivated via gene-trap; however, in
that model, gene knockout is caused by Cre-induced removal of
the floxed copy with “reactivation” of a second copy of the gene
which is silent until treated with Flp. Since gene-trap is used to ini-
tially inactivate the second copy, genes applicable for this method
need to be expressed in embryonic stem cells, and it may be diffi-
cult to predict efficiency of inactivation of the gene trapped allele
Figure 7. Increased cellular proliferation during transforming growth factor-β activated kinase 1 (TAK1) inactivation followed by differentia-
tion during Tak1 reactivation. (A): Representative immunoblot of Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvarial defects for pTAK1,
pSMAD 1/5, pSMAD 2/3, and α-tubulin. (B): Normalized quantification of pTAK1 protein expression from Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp
treated calvarial defects (Ad.LacZ: 1.0; Ad.Cre: 0.75; Ad.Cre/Ad.Flp:0.98). (C): Normalized quantification of pSMAD 1/5 protein expression from
Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvarial defects (Ad.LacZ: 1.0; Ad.Cre: 0.82; Ad.Cre/Ad.Flp: 1.43). (D): Normalized quantification of
pSMAD 2/3 protein expression from Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvarial defects (Ad.LacZ: 1.0; Ad.Cre: 0.82; Ad.Cre/Ad.Flp:
1.43). (E): Representative immunostaining of Ad.LacZ, Ad.Cre, and Ad.Cre/Ad.Flp treated calvarial defects for pTAK1. (F): Representative immu-
nostaining for PDGFRα in Ad.LacZ, Ad.Cre, Ad.Cre/Ad.Flp treated calvarial defects 9 weeks after injury. (G): Representative immunostaining for
Ki67 in Ad.LacZ, Ad.Cre, Ad.Cre/Ad.Flp treated calvarial defects 9 weeks after injury. White dotted line marks edge of native calvaria. Cells for
protein extraction collected by harvest of the calvarial defect after removal of dura. All scale bars = 200 μm; *, p < .05.
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that is known to vary gene to gene. There have been no other
reports using the LOFT approach, and no reports of a gene knock-
out/reactivation strategy for tissue regeneration [35].
In this study, we invoke a similar principle of gene inactiva-
tion and reactivation using Cre/lox and Flp/Frt technologies
but with a simpler and more straightforward targeting strategy
(COSIEN technology). Serendipitously, we found that genetic dis-
ruption of Tak1 increases proliferation and reduces differentia-
tion, leading us to wonder whether reactivation of Tak1 could
rescue cellular differentiation after a period of knockout-
induced proliferation. The dual recombinase mouse model
allowed us to study this, as pharmacologic inhibition of TAK1
with available agents does not increase proliferation. Though
an inducible siRNA strategy can be used to silence and reacti-
vate a gene, there are important distinctions between siRNA and
our COSIEN technology: (a) the COSIEN technology completely
knocks out gene function in a given cell, whereas siRNA has a
more limited knockdown, and (b) even though COSIEN recombi-
nation efficiency is not perfect, there is a mixture of knockout
cells and wild-type cells that is advantageous when cell fate spec-
ification is in question and proliferative ability of each cell is in
question.
Finally, our findings shed light on the importance of consid-
ering the effects of target inhibition and subsequent reactiva-
tion in the context of wound healing. Current efforts at tissue
regeneration are focused on reducing apoptosis and/or increas-
ing proliferation [2–5]. However, this strategy does not account
for the contribution of cellular differentiation and production of
noncellular components to tissue regeneration, primarily ECM
which is laid down by cells and forms an integral part of tissue
morphology. Other strategies which include cell transplantation
or scaffold use face hurdles to long-term incorporation and reg-
ulatory clearance. Here, we show that an approach including
target inhibition and reactivation may allow for a period of pro-
liferation followed by subsequent return of cell differentiation,
thereby reconstituting the functional tissue of interest.
ACKNOWLEDGMENTS
We thank the University of Michigan Center for Molecular
Imaging and Amanda Welton for her assistance. This work was
supported, in part. S.A. was funded by NIH F32 AR066499, NIH
Loan Repayment Program; S.J.L. and J.D. was funded by How-
ard Hughes Medical Institute (HHMI) Medical Fellows Program;
K.R. was funded by NIH F32 AR068902; Y.M. was funded by NIH
R01DE020843, DoD W81XWH-11-2-0073; M.T.L. was funded by
California Institute for Regenerative Medicine (CIRM) Clinical
Fellow Training grant TG2-01159, American Society of Maxillofa-
cial Surgeons (ASMS)/Maxillofacial Surgeons Foundation (MSF)
Research Grant Award, the Hagey Laboratory for Pediatric Regen-
erative Medicine and e Oak Foundation, NIH grant U01 HL099776,
and the Gunn/Olivier Fund; M.I. was funded by the Plastic Surgery
Foundation National Endowment Award; B.L. was funded by NIH,
NIGMS K08GM109105, NIH R01GM123069, NIH1R01AR071379,
American Association of Plastic Surgery Research Fellowship,
Plastic Surgery Foundation/AAPS Pilot Research Award, ACS
Clowes Award, and International Fibrodysplasia Ossificans Pro-
gressiva Association Research Award. Some of this work was sup-
ported by Defense Medical Research and Development Program
(Clinical and Rehabilitative Medicine Research Program [CRMRP]/
Neuromusculoskeletal Injuries Research Award [NMSIRA]) grant
CDMRP: W81XWH-14-2-0010 and Clinical and Rehabilitative
Medicine Research Program (CRMRP)/Peer Reviewed Orthope-
dic Research Program (PRORP): W81XWH-16-2-0051.
AUTHOR CONTRIBUTIONS
H.H.S.H., S.A., Y.M., B.L.: study design; H.H.S.H., S.A., D.J.C.,
S.J.L., K.K., A.H., M.T.C., K.R., J.H., J.L., J.N., J.R., A.K., J.D., C.B.,
C.R.P., C.B., J.P., S.U.O., Y.S.N., S.L., Y.M., B.L.: study conduct,
data collection, and data analysis; M.I., G.S., P.H.K., M.T.L., K.W.,
N.G., J.N.-T., Y.M., B.L.: provide critical materials; H.H.S.H., S.A.,
D.J.C., M.T.C., S.J.L., Y.M., B.L.: drafting manuscript; H.H.S.H.,
S.A., D.J.C., S.J.L., K.K., A.H., M.T.C., K.R., J.H., J.L., J.B., J.R., A.K.,
J.D., C.B., C.R.P., J.N., C.B., J.P., S.U.O., Y.S.N., S.L., M.I., G.S., P.
H.K., M.T.L., K.W., N.G., J.N.-T., Y.M., B.L.: approving final version
of manuscript; H.H.S.H., S.A., Y.M., B.L.: take responsibility for
the integrity of the data analysis.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
B.L. began collaboration with Boehringer Ingleheim after data
collection and final submission of this manuscript was complete.
N.G. declares employment/patient holder with Dana Farber Can-
cer Institute; advisory role with Syros, Gatekeeper, Soltego, B2S,
Petra, and C4 therapeutics; research funding with Taiho, Astellas,
Takeda, Vivid Biosciences, Kinogen, and Aduro; ownership inter-
est with Syros, Gatekeeper, Petra, C4, Soltego, and Aduro. The
other authors indicated no potential conflicts of interest.
DATA AVAILABILITY STATEMENT
The datasets generated during and/or analyzed during the cur-
rent study are available in the GEO Repository, GEO Submis-
sion (GSE126118; NCBI tracking system #19738436).
REFERENCES
1 Levi B, Hyun JS, Montoro DT et al. In
vivo directed differentiation of pluripotent
stem cells for skeletal regeneration. Proc Natl
Acad Sci USA 2012;109:20379–20384.
2 Levi B, Hyun JS, Nelson ER et al. Nonin-
tegrating knockdown and customized scaffold
design enhances human adipose-derived stem
cells in skeletal repair. STEM CELLS 2011;29:
2018–2029.
3 Koria P. Delivery of growth factors for
tissue regeneration and wound healing. Bio-
Drugs 2012;26:163–175.
4 Fan F, He Z, Kong LL et al. Pharmacological
targeting of kinases MST1 and MST2 augments
tissue repair and regeneration. Sci Transl Med
2016;8:352ra108.
5 Peng T, Frank DB, Kadzik RS et al. Hedge-
hog actively maintains adult lung quiescence
and regulates repair and regeneration. Nature
2015;526:578–582.
6 Zhang Y, Desai A, Yang SY et al. Tissue
regeneration. Inhibition of the prostaglandin-
degrading enzyme 15-PGDH potentiates
tissue regeneration. Science 2015;348:
aaa2340.
www.StemCells.com ©AlphaMed Press 2019
Hsieh, Agarwal, Cholok et al. 777
7 Zhang Y, Strehin I, Bedelbaeva K et al.
Drug-induced regeneration in adult mice. Sci
Transl Med 2015;7:290ra292.
8 Cheng F, Shen Y, Mohanasundaram P
et al. Vimentin coordinates fibroblast prolifer-
ation and keratinocyte differentiation in wound
healing via TGF-beta-Slug signaling. Proc Natl
Acad Sci USA 2016;113:E4320–E4327.
9 Dutta P, Sager HB, Stengel KR et al. Myo-
cardial infarction activates CCR2(+) hemato-
poietic stem and progenitor cells. Cell Stem
Cell 2015;16:477–487.
10 Leung Y, Kandyba E, Chen YB et al.
Bifunctional ectodermal stem cells around the
nail display dual fate homeostasis and adap-
tive wounding response toward nail regenera-
tion. Proc Natl Acad Sci USA 2014;111:
15114–15119.
11 Velasquez LS, Sutherland LB, Liu Z et al.
Activation of MRTF-A-dependent gene expres-
sion with a small molecule promotes myofibro-
blast differentiation and wound healing. Proc
Natl Acad Sci USA 2013;110:16850–16855.
12 Zeitouni S, Krause U, Clough BH et al.
Human mesenchymal stem cell-derived matri-
ces for enhanced osteoregeneration. Sci Transl
Med 2012;4:132ra155.
13 Zhou X, Tan M, Nyati MK et al. Blockage
of neddylation modification stimulates tumor
sphere formation in vitro and stem cell differ-
entiation and wound healing in vivo. Proc
Natl Acad Sci USA 2016;113:E2935–E2944.
14 Agarwal S, Loder S, Brownley C et al.
Inhibition of Hif1alpha prevents both trauma-
induced and genetic heterotopic ossification.
Proc Natl Acad Sci USA 2016;113:E338–E347.
15 Dey D, Bagarova J, Hatsell SJ et al. Two
tissue-resident progenitor lineages drive dis-
tinct phenotypes of heterotopic ossification.
Sci Transl Med 2016;8:366ra163.
16 Hatsell SJ, Idone V, Wolken DM et al.
ACVR1R206H receptor mutation causes fibro-
dysplasia ossificans progressiva by imparting
responsiveness to activin A. Sci Transl Med
2015;7:303ra137.
17 Yu PB, Deng DY, Lai CS et al. BMP type
I receptor inhibition reduces heterotopic
[corrected] ossification. Nat Med 2008;14:
1363–1369.
18 Agarwal S, Sorkin M, Levi B. Heterotopic
ossification and hypertrophic scars. Clin Plast
Surg 2017;44:749–755.
19 Peterson JR, De La Rosa S, Eboda O et al.
Treatment of heterotopic ossification through
remote ATP hydrolysis. Sci Transl Med 2014;6:
255ra132.
20 Ranganathan K, Loder S, Agarwal S et al.
Heterotopic ossification: Basic-science princi-
ples and clinical correlates. J Bone Joint Surg
Am 2015;97:1101–1111.
21 Bush JR, Beier F. TGF-beta and
osteoarthritis—The good and the bad. Nat
Med 2013;19:667–669.
22 Fortier LA, Barker JU, Strauss EJ et al.
The role of growth factors in cartilage repair.
Clin Orthop Relat Res 2011;469:2706–2715.
23 Greenblatt MB, Shim JH, Glimcher LH.
TAK1 mediates BMP signaling in cartilage.
Ann N Y Acad Sci 2010;1192:385–390.
24 Gunnell LM, Jonason JH, Loiselle AE et al.
TAK1 regulates cartilage and joint develop-
ment via the MAPK and BMP signaling path-
ways. J Bone Miner Res 2010;25:1784–1797.
25 Leah E. Osteoarthritis: TGF-beta overload
at bones of cartilage degeneration. Nat Rev
Rheumatol 2013;9:382.
26 Shim JH, Greenblatt MB, Xie M et al.
TAK1 is an essential regulator of BMP signal-
ling in cartilage. EMBO J 2009;28:2028–2041.
27 Zhen G, Wen C, Jia X et al. Inhibition of
TGF-beta signaling in mesenchymal stem cells
of subchondral bone attenuates osteoarthri-
tis. Nat Med 2013;19:704–712.
28 Zhao T, Ren H, Jia L et al. Inhibition of
HIF-1alpha by PX-478 enhances the anti-tumor
effect of gemcitabine by inducing immuno-
genic cell death in pancreatic ductal adenocar-
cinoma. Oncotarget 2015;6:2250–2262.
29 Mihaly SR, Ninomiya-Tsuji J, Morioka S.
TAK1 control of cell death. Cell Death Differ
2014;21:1667–1676.
30 Sato S, Sanjo H, Takeda K et al. Essential
function for the kinase TAK1 in innate and
adaptive immune responses. Nat Immunol
2005;6:1087–1095.
31 Ninomiya-Tsuji J, Kajino T, Ono K et al. A
resorcylic acid lactone, 5Z-7-oxozeaenol, pre-
vents inflammation by inhibiting the catalytic
activity of TAK1 MAPK kinase kinase. J Biol
Chem 2003;278:18485–18490.
32 Minoda Y, Sakurai H, Kobayashi T et al.
An F-box protein, FBXW5, negatively regulates
TAK1 MAP3K in the IL-1beta signaling path-
way. Biochem Biophys Res Commun 2009;
381:412–417.
33 Moding EJ, Lee CL, Castle KD et al. Atm
deletion with dual recombinase technology
preferentially radiosensitizes tumor endothe-
lium. J Clin Invest 2014;124:3325–3338.
34 Schonhuber N, Seidler B, Schuck K et al.
A next-generation dual-recombinase system
for time- and host-specific targeting of pan-
creatic cancer. Nat Med 2014;20:1340–1347.
35 Chaiyachati BH, Kaundal R, Zhao J et al.
LoxP-FRT Trap (LOFT): A simple and flexible
system for conventional and reversible gene
targeting. BMC Biol 2012;10:96.
36 Levi B, James AW, Xu Y et al. Divergent
modulation of adipose-derived stromal cell dif-
ferentiation by TGF-beta1 based on species of
derivation. Plast Reconstr Surg 2010 Aug;126:
412–425.
37 James AW, Levi B, Commons GW et al.
Paracrine interaction between adipose-derived
stromal cells and cranial suture-derived mesen-
chymal cells. Plast Reconstr Surg 2010 Sep;126:
806–821.
38 Levi B, Nelson ER, Brown K et al. Differ-
ences in osteogenic differentiation of adipose-
derived stromal cells from murine, canine, and
human sources in vitro and in vivo. Plast
Reconstr Surg 2011 Aug;128:373–386.
39 Levi B, Longaker MT. Osteogenic differenti-
ation of adipose-derived stromal cells in mouse
and human: in vitro and in vivo methods.
J Craniofac Surg, 2011;22:388–391.
See www.StemCells.com for supporting information available online.
©AlphaMed Press 2019 STEM CELLS
778 Coordinating Tissue Regeneration Through TAK1
